Research landscape on COVID-19 and liver dysfunction: A bibliometric analysis.
Bibliometric
COVID-19
Liver
Scopus
Vosviewer
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Jul 2023
21 Jul 2023
Historique:
received:
24
02
2023
revised:
16
06
2023
accepted:
27
06
2023
medline:
8
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
The global spread of severe acute respiratory syndrome coronavirus 2, responsible for coronavirus disease 2019 (COVID-19), poses a significant risk to public health. Beyond the respiratory issues initially associated with the condition, severe cases of COVID-19 can also lead to complications in other organs, including the liver. Patients with severe COVID-19 may exhibit various clinical signs of liver dysfunction, ranging from minor elevations in liver enzymes without symptoms to more serious cases of impaired liver function. Liver damage is more commonly observed in patients with severe or critical forms of the disease. To present the research landscape on COVID-19 and liver dysfunction while also offering valuable insights into the prominent areas of interest within this particular domain. On 18 February 2023, Scopus was utilised to conduct a comprehensive exploration of the relationship between COVID-19 and the liver dysfunction. The investigation encompassed the period from 1 January 2020 to 31 December 2022. Primary sources were meticulously examined and organised in a Microsoft Excel 2013 spreadsheet, categorised by journal, institution, funding agency, country and citation type. VOSviewer version 1.6.18 was employed to explore the prominent topics and knowledge network related to the subject. There were 2336 publications on COVID-19 and liver dysfunction analysed in this study, of which 558 were published in 2020, 891 in 2021 and 887 in 2022. Researchers from 111 different countries participated in the retrieved documents. The United States contributed the most studies, with 497 documents, representing 21.28% of the total, followed by China with 393 documents (16.82%) and Italy with 255 documents (10.92%). In the context of research related to COVID-19 and the liver, co-occurrence analysis identified three distinct clusters of topics: (1) 'COVID-19 vaccines in liver transplant recipients'; (2) 'liver function tests as a predictor of the severity and clinical outcomes in hospitalised patients'; and (3) 'care of patients with liver disease during the COVID-19 pandemic'. This bibliometric study provides a comprehensive overview of liver-related publications in COVID-19 research over the past 3 years. This study highlights the significant contributions of high-income nations, particularly the United States, China, and Italy, to the production of liver-related scholarly literature in this field. Most of the articles focused on liver dysfunction in patients with COVID-19 and the implications of the virus for gastroenterologists and hepatologists.
Sections du résumé
BACKGROUND
BACKGROUND
The global spread of severe acute respiratory syndrome coronavirus 2, responsible for coronavirus disease 2019 (COVID-19), poses a significant risk to public health. Beyond the respiratory issues initially associated with the condition, severe cases of COVID-19 can also lead to complications in other organs, including the liver. Patients with severe COVID-19 may exhibit various clinical signs of liver dysfunction, ranging from minor elevations in liver enzymes without symptoms to more serious cases of impaired liver function. Liver damage is more commonly observed in patients with severe or critical forms of the disease.
AIM
OBJECTIVE
To present the research landscape on COVID-19 and liver dysfunction while also offering valuable insights into the prominent areas of interest within this particular domain.
METHODS
METHODS
On 18 February 2023, Scopus was utilised to conduct a comprehensive exploration of the relationship between COVID-19 and the liver dysfunction. The investigation encompassed the period from 1 January 2020 to 31 December 2022. Primary sources were meticulously examined and organised in a Microsoft Excel 2013 spreadsheet, categorised by journal, institution, funding agency, country and citation type. VOSviewer version 1.6.18 was employed to explore the prominent topics and knowledge network related to the subject.
RESULTS
RESULTS
There were 2336 publications on COVID-19 and liver dysfunction analysed in this study, of which 558 were published in 2020, 891 in 2021 and 887 in 2022. Researchers from 111 different countries participated in the retrieved documents. The United States contributed the most studies, with 497 documents, representing 21.28% of the total, followed by China with 393 documents (16.82%) and Italy with 255 documents (10.92%). In the context of research related to COVID-19 and the liver, co-occurrence analysis identified three distinct clusters of topics: (1) 'COVID-19 vaccines in liver transplant recipients'; (2) 'liver function tests as a predictor of the severity and clinical outcomes in hospitalised patients'; and (3) 'care of patients with liver disease during the COVID-19 pandemic'.
CONCLUSION
CONCLUSIONS
This bibliometric study provides a comprehensive overview of liver-related publications in COVID-19 research over the past 3 years. This study highlights the significant contributions of high-income nations, particularly the United States, China, and Italy, to the production of liver-related scholarly literature in this field. Most of the articles focused on liver dysfunction in patients with COVID-19 and the implications of the virus for gastroenterologists and hepatologists.
Identifiants
pubmed: 37545639
doi: 10.3748/wjg.v29.i27.4356
pmc: PMC10401660
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4356-4367Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Références
Turk J Med Sci. 2020 Apr 15;50(SI-1):571-577
pubmed: 32293835
Infect Drug Resist. 2022 May 12;15:2469-2474
pubmed: 35592105
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Am J Trop Med Hyg. 2022 Feb 24;:
pubmed: 35203056
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102325
pubmed: 34739909
Cureus. 2020 Aug 24;12(8):e9999
pubmed: 32983698
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Rheumatol Int. 2021 Dec;41(12):2091-2103
pubmed: 34596719
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
J Hepatol. 2020 Aug;73(2):451-453
pubmed: 32278005
J Hepatol. 2020 Oct;73(4):807-816
pubmed: 32437830
Prev Chronic Dis. 2022 Aug 25;19:E53
pubmed: 36007255
World J Orthop. 2022 Oct 18;13(10):891-902
pubmed: 36312521
J Health Popul Nutr. 2023 May 12;42(1):42
pubmed: 37173756
Scientometrics. 2017;111(2):1053-1070
pubmed: 28490825
Am J Gastroenterol. 2020 Jul;115(7):1075-1083
pubmed: 32618658
Global Health. 2022 Jan 21;18(1):4
pubmed: 35062966
Eur J Med Res. 2020 Nov 4;25(1):54
pubmed: 33148326
J Hepatol. 2021 Mar;74(3):567-577
pubmed: 33035628
Liver Int. 2020 Sep;40(9):2095-2103
pubmed: 32239796
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Health Popul Nutr. 2023 Jan 18;42(1):3
pubmed: 36653831
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):529-530
pubmed: 32203680
Eur Rev Med Pharmacol Sci. 2020 Dec;24(24):13072-13088
pubmed: 33378061
World J Hepatol. 2021 Dec 27;13(12):2013-2023
pubmed: 35070005
JAMA. 2009 Sep 9;302(10):1092-6
pubmed: 19738094
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
World J Gastroenterol. 2021 Sep 14;27(34):5630-5665
pubmed: 34629792
Cureus. 2020 Oct 13;12(10):e10923
pubmed: 33194489
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
World J Gastroenterol. 2022 Dec 7;28(45):6314-6327
pubmed: 36533104
Nurs Outlook. 2017 Sep - Oct;65(5):572-578
pubmed: 28377037
Ann Otol Rhinol Laryngol. 2023 Feb;132(2):164-172
pubmed: 35240864
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):9437-42
pubmed: 24979796
Biomolecules. 2023 Jan 03;13(1):
pubmed: 36671484
Ann Hepatol. 2022 Jan-Feb;27(1):100653
pubmed: 34929350
Eur J Gastroenterol Hepatol. 2021 Jan;33(1):114-115
pubmed: 32282549
World J Gastroenterol. 2022 Oct 7;28(37):5383-5394
pubmed: 36312837
Gastroenterol Hepatol Bed Bench. 2020 Fall;13(4):292-304
pubmed: 33244371
World J Gastrointest Surg. 2022 May 27;14(5):494-505
pubmed: 35734615
Clin Mol Hepatol. 2022 Oct;28(4):890-911
pubmed: 36263669
Hepatol Res. 2020 Aug;50(8):924-935
pubmed: 32386449
Gut. 2020 Aug;69(8):1545-1547
pubmed: 32414813
J Hepatol. 2023 May;78(5):1017-1027
pubmed: 36804404
Scientometrics. 2010 Aug;84(2):523-538
pubmed: 20585380
Glob Health Res Policy. 2018 Oct 22;3:30
pubmed: 30377667
Medicina (Kaunas). 2022 Nov 21;58(11):
pubmed: 36422225
Int J Biol Sci. 2022 Sep 21;18(15):5849-5857
pubmed: 36263175
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):1008-1016
pubmed: 32866433
World J Clin Cases. 2021 Aug 6;9(22):6178-6200
pubmed: 34434987
Saudi J Gastroenterol. 2021 Jul-Aug;27(4):201-207
pubmed: 34100388
Int J Pharm Pract. 2019 Apr;27(2):112-120
pubmed: 30044514
Clin Exp Hepatol. 2021 Sep;7(3):297-304
pubmed: 34712832
World J Clin Cases. 2022 Oct 16;10(29):10391-10398
pubmed: 36312463
World J Psychiatry. 2021 Jun 19;11(6):253-264
pubmed: 34168972
J Hepatol. 2020 Sep;73(3):566-574
pubmed: 32298767
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
Clin Res Hepatol Gastroenterol. 2021 Jul;45(4):101639
pubmed: 33636654
J Clin Transl Hepatol. 2020 Mar 28;8(1):13-17
pubmed: 32274341
Transplantation. 2021 Jan 1;105(1):37-55
pubmed: 33148977
Trends Food Sci Technol. 2022 Feb;120:174-192
pubmed: 35002079
JHEP Rep. 2020 Jun;2(3):100113
pubmed: 32289115
Hist Psychol. 2018 Nov;21(4):334-362
pubmed: 28726441
Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566
pubmed: 32283325
Global Health. 2021 Sep 23;17(1):114
pubmed: 34556126
Hepatology. 2021 Apr;73(4):1509-1520
pubmed: 32602604
Front Public Health. 2022 Dec 08;10:1022810
pubmed: 36568760
Front Cardiovasc Med. 2022 Jul 27;9:955237
pubmed: 35966543
J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24
pubmed: 32274342
World J Hepatol. 2022 Dec 27;14(12):2012-2024
pubmed: 36618330
Arab J Gastroenterol. 2020 Mar;21(1):3-8
pubmed: 32253172
Health Info Libr J. 2015 Dec;32(4):255-64
pubmed: 26123736
Front Public Health. 2023 Feb 02;11:1003352
pubmed: 36817905
World J Gastroenterol. 2022 Feb 7;28(5):570-587
pubmed: 35316959
World J Gastroenterol. 2022 Dec 28;28(48):6791-6810
pubmed: 36632314
Nurs Outlook. 2012 Nov-Dec;60(6):391-400
pubmed: 22748758
Front Immunol. 2022 Oct 31;13:1035151
pubmed: 36405695
SN Compr Clin Med. 2021;3(8):1699-1703
pubmed: 33997623
Hepatol Int. 2020 Sep;14(5):881-883
pubmed: 32725454
Ann Hepatol. 2020 Nov - Dec;19(6):627-634
pubmed: 32882393
Sci Rep. 2021 May 19;11(1):10599
pubmed: 34012016
World J Hepatol. 2021 Dec 27;13(12):1909-1918
pubmed: 35069997